patients with cirrhosis in a randomized controlled trial.” Kwo emphasized the potential benefits of using SGLT2 inhibitors in this patient population, suggesting that further research is needed to fully understand the efficacy and safety of this treatment approach.
Source link
VIDEO: ‘We should be exploring’ sodium-glucose inhibitors in cirrhosis treatment
